In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy
Session

Congress : Heart Failure 2018

Topic : Chronic Heart Failure

  • Session type : Satellite Symposium - Experts on the Spot
  • Date : 27 May 2018
  • Time : 15:55 - 16:25
  • Sponsored by Vifor Pharma

3 presentations in this session

Introduction - Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy.

Congress : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by Vifor Pharma

Clinical case discussion.

Congress : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy
  • Speaker : J Comin-Colet (Hospitalet De Llobregat,ES), J Butler (Atlanta,US)
  • Sponsored by Vifor Pharma

Conclusions - Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy.

Congress : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by Vifor Pharma

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are